Cochrane Abstracts
Ocriplasmin for symptomatic vitreomacular adhesion
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Ocriplasmin for Symptomatic Vitreomacular Adhesion." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/436772/0/Ocriplasmin_for_symptomatic_vitreomacular_adhesion.
Ocriplasmin for symptomatic vitreomacular adhesion. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436772/0/Ocriplasmin_for_symptomatic_vitreomacular_adhesion. Accessed December 8, 2024.
Ocriplasmin for symptomatic vitreomacular adhesion. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436772/0/Ocriplasmin_for_symptomatic_vitreomacular_adhesion
Ocriplasmin for Symptomatic Vitreomacular Adhesion [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 08]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/436772/0/Ocriplasmin_for_symptomatic_vitreomacular_adhesion.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ocriplasmin for symptomatic vitreomacular adhesion
ID - 436772
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/436772/0/Ocriplasmin_for_symptomatic_vitreomacular_adhesion
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
